For information regarding recent FDA correspondence, please read the press release.

Patients & Caregivers Website Healthcare Professionals Website
Dramatic close-up portrait of a confident elderly woman with short silver-gray cropped hair, deep expressive wrinkles, piercing gaze through round clear-framed glasses, large gold hoop earrings, illuminated by vibrant cyan and magenta neon lighting creating a striking high-contrast cyberpunk effect against dark background
Not an actual patient.

Know the Enemy.

Nonmuscle invasive bladder cancer (NMIBC).

Diagram illustrating intravesical instillation for non-muscle invasive bladder cancer (NMIBC): a simplified cross-section of the bladder and urethra with a catheter inserted, showing BCG bacteria (purple ovals) coating the bladder wall and ANKTIVA molecules (green Y-shaped structures with orange spheres) binding nearby, labeled with "Bladder", "Catheter", "BCG", "Anktiva", and "NMIBCBC"

The standard of care for intermediate or high-risk nonmuscle invasive bladder cancer (NMIBC) patients is transurethral resection of the bladder tumor (TURBT) followed by Bacillus Calmette-Guérin (BCG) intravesical instillation. Yet up to 40% of these patients will have a recurrence despite these interventions. And half of patients who exhibit complete response will suffer a relapse.1

Anktiva plus BCG also can be administered by most urologists in their own clinics, without the need for special facilities or complex procedures.

Anktiva delivered in combination with BCG through intravesical instillation uses the power of the immune system to boost the efficacy of BCG, delivering a complete response with long-term durability in a majority of patients in a pivotal trial.

Anktiva plus BCG, when administered intravesically, is well tolerated.2

4 out of 5 people with bladder cancer have NMIBC.3 For an estimated 30-40 percent of patients, BCG therapy may not work long term.

1. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2011;49:466-477. DOI: 10.1016/j.eururo.2005.12.031. 2. Anktiva Package insert. lmmunityBio, Inc.; 2024. 3 Grabe-Heyne, K. et al. Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs. Frontiers in Oncology Jun 2 2023; 13: 1170124. doi: 10.3389/fonc.2023.1170124. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272547/

How to Order

A step-by-step guide on how to order Anktiva, including product codes.

Download

Patient Stories

Patients Like You

Read about patients who participated in the clinical trials for Anktiva

Justin’s Journey

Justin’s Journey

An avid outdoorsman, Justin faced a challenging diagnosis of non-muscle invasive bladder cancer. After struggling with the side effects of his Bacillus Calmette-Guérin (BCG) treatment, he found renewed hope though his doctors' introduction to an immunotherapy for those who experienced a recurrence of NMIBC.

Learn More

Wayne’s Journey

Wayne’s Journey

Wayne has lived a rich life with his wife, two daughters, and three grandchildren. He describes himself as someone who “just likes people.” When he was first told, “you might have a tumor in your bladder,” he became very concerned, especially when he learned his first treatment with BCG wasn’t working. Wayne feels lucky that a friend told him about a clinical trial for patients like himself who were not cured by BCG alone.

Learn More

See All Stories

Anktiva Resources

DATASHEET

How to Order

A step-by-step guide on how to order Anktiva, including product codes

Download PDF

Video

Physicians' Journey

Listen to the physicians' journey with their patients using Anktiva.

Watch Video

See All Resources
Indication and Important Safety Information

INDICATION AND USAGE

ANKTIVA is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

WARNINGS AND PRECAUTIONS

Risk of Metastatic Bladder Cancer with Delayed Cystectomy. Delaying cystectomy can lead to the development of muscle invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after a second induction course of ANKTIVA with BCG, reconsider cystectomy.

DOSAGE AND ADMINISTRATION

For lntravesical Use Only. Do not administer by subcutaneous or intravenous routes. Instill intravesically only after dilution. Total time from vial puncture to the completion of the intravesical instillation should not exceed 2 hours.

USE IN SPECIFIC POPULATIONS

Pregnancy: May cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.

ADVERSE REACTIONS

The most common (≥15%) adverse reactions, including laboratory test abnormalities, are increased creatinine, dysuria, hematuria, urinary frequency, micturition urgency, urinary tract infection, increased potassium, musculoskeletal pain, chills and pyrexia.

For more information about ANKTIVA, please see the Full Prescribing Information at www.anktiva.com.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch or call 1-800-332-1088. You may also contact lmmunityBio at 1-877-ANKTIVA (1-877-265-8482)

When BCG Alone Isn’t Enough,

Bring On the Tri-Offense With Anktiva.

For more information, please call 1-877-ANKTIVA.

The information contained in this section of the site is intended for US healthcare professionals only. Click “Continue” if you are a healthcare professional.

Continue Visit Patient Site